Lb Pharmaceuticals (LBRX) Cash from Financing Activities (2025 - 2026)
Lb Pharmaceuticals' (LBRX) quarterly Cash from Financing Activities came in at $93.8 million in Q1 2026, up 8119.74% quarter-over-quarter from -$1.2 million in Q4 2025.
Lb Pharmaceuticals (LBRX) Cash from Financing Activities (2025 - 2026) Analysis & Trends
Lb Pharmaceuticals' Cash from Financing Activities history runs 2 years deep, the most recent figure standing at $93.8 million for Q1 2026.
- On a quarterly basis, Cash from Financing Activities changed N/A year-over-year to $93.8 million in Q1 2026; TTM through Mar 2026 was $92.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $302.6 million, up 689.67% from the prior year.
- Cash from Financing Activities climbed to $93.8 million in Q1 2026 per LBRX's latest filing, from -$1.2 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $93.8 million in Q1 2026 and bottomed at -$1.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Lb Pharmaceuticals | 977.73 Mn | 977.73 Mn | - | 93.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 93.83 Mn |
| Mar 31, 2026 | 93.83 Mn |
| Dec 31, 2025 | -1.17 Mn |
| Dec 31, 2025 | -1.17 Mn |